Lantheus (NASDAQ:LNTH – Get Free Report) released its earnings results on Thursday. The medical equipment provider reported $1.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.45, FiscalAI reports. Lantheus had a net margin of 17.28% and a return on equity of 29.26%. The firm had revenue of $389.91 million during the quarter, compared to analyst estimates of $355.74 million. During the same quarter last year, the business earned $1.27 EPS. The business’s revenue was up 1.5% on a year-over-year basis.
Lantheus Stock Performance
LNTH stock traded down $0.09 during trading on Friday, hitting $100.61. 1,575,979 shares of the company traded hands, compared to its average volume of 1,090,931. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.25 and a quick ratio of 2.89. The company has a market cap of $6.57 billion, a PE ratio of 24.78 and a beta of 0.01. The stock’s 50-day simple moving average is $100.27 and its 200 day simple moving average is $92.06. Lantheus has a 1 year low of $50.15 and a 1 year high of $111.86.
Analyst Ratings Changes
LNTH has been the subject of several research reports. Weiss Ratings cut shares of Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, October 15th. Leerink Partners set a $102.50 target price on Lantheus in a research report on Monday, August 3rd. B. Riley Financial lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th. Mizuho downgraded Lantheus from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $115.00 to $109.00 in a report on Tuesday, October 13th. Finally, William Blair set a $102.50 price target on shares of Lantheus in a report on Monday, August 3rd. Three investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Lantheus has a consensus rating of “Hold” and a consensus price target of $107.44.
Check Out Our Latest Report on LNTH
About Lantheus
Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.
The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.
Read More
- Five stocks we like better than Lantheus
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
